High risk of graft failure in patients with anti-hla antibodies undergoing haploidentical stem-cell transplantation

Transplantation

Volumn 88, Issue 8, 2009, Pages 1019-1024

  Ciurea, Stefan O ^a   De Lima, Marcos ^a   Cano, Pedro ^a   Korbling, Martin ^a   Giralt, Sergio ^a   Shpall, Elizabeth J ^a   Wang, Xuemei ^a   Thall, Peter F ^a   Champlin, Richard E ^a   Fernandez Vina, Marcelo ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Donor specific anti HLA antibodies; Haploidentical stem cell transplantation.; Primary graft failure

Indexed keywords

ALEMTUZUMAB; CASPOFUNGIN; COTRIMOXAZOLE; FLUDARABINE; GANCICLOVIR; HLA ANTIBODY; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; VALACICLOVIR; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLELE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFECTION; LYMPHOMA; MALE; MYELODYSPLASTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY AND SPECIFICITY;

ANTIGENS, CD; ANTIGENS, CD34; FAMILY; FEMALE; FILGRASTIM; GRAFT REJECTION; HAPLOIDY; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; ISOANTIGENS; LYMPHOCYTE DEPLETION; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TISSUE DONORS; TREATMENT FAILURE;

EID: 70350463957     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b9d710     Document Type: Article

References (31)

1. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593.
2. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype. N Eng J Med 1998; 339: 1186.
3. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813.
4. Powles R. Long-term remissions in acute myelogenous leukaemia. Lancet 1984; 1: 800.
5. Beatty PG, Clift RA, Mikelson EM, et al. Marrow transplantation from related donors other then HLA-identical siblings. N Engl J Med 1995; 313: 765.
6. Bachar-Lustig E, Rachamim N, Li HW, et al. Megadose of T-cell depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995; 1: 1268.
7. Lang P, Greil J, Bader P, et al. Long-term outcome after haploiden-tical stem cell transplantation in children. Blood Cells Mol Dis 2004; 33: 281.
8. Ciceri F, Labopin M, Aversa F, et al. A survey of fully-haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia:Arisk factor analysisofoutcomes for patients transplanted in remission. Blood 2008; 112: 3574.
9. Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant 2007; 13: 1249.
10. Patel R, Terasaki PI. Significance of positive crossmatch in kidney transplantation. N Engl J Med 1969; 280: 735.
11. Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med 1994; 331: 765.
12. Suciu-Foca N,Reed E, MarboeC, et al. The role ofanti-HLA antibodies in heart transplantation. Transplantation 1991; 51: 716.
13. Terasaki PI, Ozawa MA. Predicting kidney graft failure by HLA antibodies a prospective trial. Am J Transplant 2004; 4: 438.
14. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance ofHLA antibodies and failure of kidney graftsin afive-year longitudinal study. Am J Transplant 2007; 7: 864.
15. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319.
16. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 2006; 6: 2307.
17. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplantsin patients with leukemia and lymphoma. N Engl J Med 1989; 320: 197.
18. Ottinger HD, RebmannV, Pfeiffer KA,et al. Positive serum crossmatch as predictor for graft failurein HLA-mismatched allogeneic blood stem cell transplantation. Transplantation 2002; 73: 1280.
19. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008; 69: 591.
20. Taylor PA, Ehrhart MJ, Roforth MM, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraft-ment in allosensitized recipients. Blood 2007; 109: 1307.
21. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of HLA antibody specificities. Transplantation 2003; 75: 43.
22. Miltenyi S, Muller W, Weichel W, et al. High gradient magnetic cell separation with MACS. Cytometry 1990; 11: 231.
23. Ciurea SO, Qureshi S, Rondon G, et al. Sustained engraftment using fludarabine, melphalan and thiotepa conditioning for haploidentical stem cell transplantation. Blood 2007; 351B: 5081a.
24. Smith JD, Hamour IM, Banner NR, et al. C4d fixing, luminex binding antibodies a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
25. Fisher RA. On the interpretation of x from contingency tables, and the calculation of P. J R Stat Soc 1922; 85: 87.
26. Karim HF, Mehta CR, Patel NR. Computing distributions for exact logistic regression. J Am Stat Assoc 1987; 82: 1110.
27. Randles RH, Wolfe DA. Introduction to the theory of nonparametric statistics. New York, John Wiley 1979.
28. Xu H, Chilton PM, Tanner MK, et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 2006; 108: 3611.
29. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
30. Bearden CM, Agarwal A, Book BK, et al. Rituximab (Rituxan) inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005; 5: 50.
31. Mizutani K, Terasaki P, Bignon JD, et al. Association of kidney transplant failure and antibodies against MICA. Hum Immunol 2006; 67: 683